All relevant data are within the paper.

Introduction {#sec001}
============

Epstein-Barr virus (EBV), also referred to as human herpesvirus 4 (HHV-4), is the first identified human virus with documented involvement in carcinogenesis \[[@pone.0140178.ref001]\]. Many cells of the non-Hodgkin lymphomas (NHL) show the presence of the monoclonal form of EBV genome (i.e. the EBV-positive phenotype). This finding points to the origin of the malignancy from a single infected cell and involvement of EBV in its pathogenesis \[[@pone.0140178.ref002], [@pone.0140178.ref003]\]. A number of hypotheses have been proposed to explain the etiology of NHL in individuals from the general population with inadequately controlled EBV infection. One postulated mechanism is the EBV-induced proliferation of B lymphocytes and a resultant increase in the number of B-cells at risk of oncogenic mutations and clonal expansion \[[@pone.0140178.ref004]\].

Despite its chronic character by definition, chronic lymphocytic leukemia (CLL) is characterized by marked heterogeneity \[[@pone.0140178.ref005], [@pone.0140178.ref006]\]. Only 30% of patients survive up to 10--20 years after diagnosis \[[@pone.0140178.ref007]\]. The remaining CLL patients develop terminal phase within 5--10 years, despite mild onset of the disease. The individuals with the aggressive form of CLL survive no more than 2--3 years after diagnosis \[[@pone.0140178.ref008]\]. The reasons for such heterogeneous natural history of the condition remain unclear.

Potential involvement of EBV in the clinical course of CLL is still unexplained. Latent EBV infection is controlled by a cell-mediated immune response in healthy carriers. This immune response is impaired in CLL patients and might result in poor control of reactivation and replication of the virus. Since EBV may activate B cells, stimulate their proliferation, and inhibit their apoptosis, we hypothesized that it could contribute to unfavorable clinical course of CLL and may be one of the reasons for the observed disease heterogeneity.

The aim of this study was to define a role of EBV in the etiopathogenesis of CLL. The detailed objectives included the determination of the EBV-DNA copy number in mononuclear cells and isolated B lymphocytes from peripheral blood of CLL patients and healthy individuals and the analysis of association between this parameter and the established prognostic factors, stage of the disease, and its clinical manifestation.

Methods {#sec002}
=======

Characteristics of CLL patients and healthy volunteers {#sec003}
------------------------------------------------------

The study included peripheral blood samples from 115 previously untreated patients with CLL (54 women and 61 men). The control group comprised 40 healthy subjects (16 women and 24 men). Neither the CLL patients nor the controls used immunomodulating agents or hormonal preparations, showed signs of infection within at least 3 months prior to the study, underwent blood transfusion, or presented with autoimmune condition or allergy. Moreover, none of the controls had a history of oncological therapy or prior treatment for tuberculosis or other chronic conditions that could be associated with impaired cellular or humoral immunity.

The diagnosis of CLL was established on the basis of diagnostic criteria included in the IWCLL guidelines of the American National Cancer Institute (NCI) \[[@pone.0140178.ref009], [@pone.0140178.ref010]\]. Detailed characteristics of patients and controls are presented in [Table 1](#pone.0140178.t001){ref-type="table"} and [Table 2](#pone.0140178.t002){ref-type="table"}.

10.1371/journal.pone.0140178.t001

###### Characteristics of chronic lymphocytic leukemia (CLL) patients and univariable analysis for time to first treatment.
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  ------------------------------------------------------------------- ------------------------ ------------------------------------ -------------------------------- -------------
  **Parameter**                                                       **Median (range)**       **Mean±SD**                          **Hazard ratio (95%CI)**         **P value**
  Age (years)                                                         64 (38--89)              63.27±9.73                           0.99 (0.97--1.03)                0.92
  Observation period (months)                                         33 (10.50--80)           34.05±13.39                          \-                               \-
  Lymphocyte doubling time (months)                                   8.75 (0.25--94)          14.70±17.02                          0.97 (0.95--0.99)                0.012
  Time from diagnosis to initiation of treatment (months)             13 (0.25--72)            17.88±15.86                          \-                               \-
  White blood cell count, WBC (G/L)                                   30.19 (9.70--128)        37.09±22.94                          0.99 (0.98--1.00)                0.29
  Lymphocytosis (G/L)                                                 24.55 (6.16--124)        31.09±22.16                          0.99 (0.98--1.00)                0.29
  Hemoglobin (g/dL)                                                   13 (9--16.8)             13.05±1.69                           0.78 (0.65--0.94)                0.011
  Platelets (G/L)                                                     172 (57--309)            174.77±58.36                         1.00 (0.99--1.00)                0.28
  Lactate dehydrogenase, LDH (U/L)                                    298 (96--955)            306.63±133.02                        1.00 (1.00--1.004)               0.018
  Beta-2 microglobulin, B2M (mg/L)                                    2.53 (1.10--8.14)        2.83±1.24                            1.40 (1.12--1.74)                0.0028
  IgA (g/L)                                                           1.21 (0.13--5.40)        1.44±1.06                            0.91 (0.69--1.22)                0.54
  IgG (g/L)                                                           8.85 (3.18--19.41)       9.15±3.64                            1.05 (0.96--1.15)                0.28
  IgM (g/L)                                                           0.5 (0.04--3.13)         0.66±0.52                            1.37 (0.75--2.47)                0.30
  EBV-DNA copies/μg DNA                                               18.0 (0.0--8957.7)       428.47±1180.4                        1.0002 (1.00004--1.0003)         0.013
  CD19+CD25+ cells \[%\] [\*](#t001fn001){ref-type="table-fn"}        54.75 (6.72--93.87)      54.96±20.50                          1.03 (1.01--1.05)                0.0001
  CD19+CD69+ cells \[%\] [\*](#t001fn001){ref-type="table-fn"}        28.73 (0.55--78.82)      31.06±19.53                          1.02 (1.00--1.04)                0.0083
  CD3+CD25+ cells \[%\] [\*](#t001fn001){ref-type="table-fn"}         18.37 (0.63--59.38)      19.89±14.39                          1.019 (0.998--1.041)             0.080
  CD3+CD69+ cells \[%\] [\*](#t001fn001){ref-type="table-fn"}         3.07 (0.06--29.32)       4.64±4.70                            1.07 (1.02--1.13)                0.0090
  CD19+CD5+ZAP-70+ cells \[%\][\*](#t001fn001){ref-type="table-fn"}   14.19 (0.18--91.4)       16.30±12.80                          1.012 (0.99--1.032)              0.22
  CD19+CD5+CD38+ cells \[%\][\*](#t001fn001){ref-type="table-fn"}     9.01 (0.18--91.4)        22.95±25.85                          1.02 (1.01--1.03)                0.00031
  CD19+CD5+CD23+ cells \[%\] [\*](#t001fn001){ref-type="table-fn"}    80.38 (46.05--95.88)     78.69±12.55                          1.02 (1.00--1.05)                0.034
  Anti-EBV EA IgA                                                     5.20 (1.0--580.38)       30.50±86.20                          1.004 (0.999--1.009)             0.15
  Anti-EBV EA IgG                                                     13.58 (1.92--381.1)      54.38±86.17                          1.004 (1.00--1.007)              0.014
  Anti-EBV EA IgM                                                     3.81 (0.79--62.70)       5.96±7.9                             1.001 (0.98--1.027)              0.89
  Anti-EBV EBNA-1 IgA                                                 5.43 (1.24--78.51)       8.86±10.98                           1.011 (0.99--1.035)              0.33
  Anti-EBV EBNA-1 IgG                                                 65.76 (22.41--1701.82)   146.53±253.94                        1.001 (1.0003--1.002)            0.008
  Anti-EBV EBNA-1 IgM                                                 5.52 (0.89--20.72)       6.34±4.22                            1.017 (0.96--1.082)              0.60
  Anti-EBV VCA IgA                                                    6.95 (1.87--50.90)       10.55±8.75                           1.027 (0.99--1.061)              0.099
  Anti-EBV VCA IgG                                                    183.74 (23.80--358.05)   180.89±91.26                         1.006 (1.002--1.010)             0.0062
  **Parameter**                                                       **Number of patients**   **Percentages (%)**                  **Hazard ratio (95%CI)**         **P value**
  Rai Stage                                                                                                                                                          
  0                                                                   48                       41.74%                               II-IV v 0--1:0.84 (0.46--1.53)   0.57
  I                                                                   27                       23.48%                                                                
  II                                                                  30                       26.09%                                                                
  III                                                                 2                        1.74%                                                                 
  IV                                                                  8                        6.96%                                                                 
  Binet classification                                                                                                                                               
  A                                                                   48                       41.74%                               baseline                         
  B                                                                   57                       49.57%                               1.02 (0.48--2.16)                0.96
  C                                                                   10                       8.69%                                1.24 (0.47--3.27)                0.68
  Splenomegaly                                                                                                                                                       
  Yes                                                                 35                       30.43%                               1.87 (1.02--3.44)                0.043
  No                                                                  80                       69.57%                               baseline                         
  Hepatomegaly                                                                                                                                                       
  Yes                                                                 19                       16.52%                               1.33 (0.68--2.60)                0.41
  No                                                                  96                       83.48%                               baseline                         
  Doubling lymphocytosis in observation period                                                                                                                       
  Yes                                                                 68                       59.13%                               2.28 (0.88--5.95)                0.09
  No                                                                  47                       40.87%                               baseline                         
  Length of lymphocyte doubling time                                                                                                                                 
  shorter than 6 months                                               22                       32.35 (19.13% among all patients)                                     
  6--12 months                                                        24                       35.30 (20.87% among all patients)                                     
  longer than 12 months                                               22                       32.35 (19.13% among all patients)                                     
  Treatment onset in observation period                                                                                                                              
  Yes                                                                 45                       39.13%                               5.66 (0.76--42.08)               0.09
  No                                                                  70                       60.87%                               baseline                         
  Outcome                                                                                                                                                            
  Complete remission after treatment                                  10                       21.28% (8.69% among all patients)                                     
  Partial remission after treatment                                   5                        10.64% (4.35% among all patients)                                     
  Progressive disease                                                 24                       51.06% (20.87% among all patients)                                    
  CLL-associated deaths                                               8                        17.02% (6.96% among all patients)                                     
  ZAP-70 (cut-off 20%)                                                                                                                                               
  Positive                                                            41                       35.65%                               1.35 (0.74--2.46)                0.33
  Negative                                                            74                       64.35%                               baseline                         
  CD38 (cut-off 30%)                                                                                                                                                 
  Positive                                                            43                       37.39%                               2.82 (1.42--5.62)                0.0032
  Negative                                                            72                       62.61%                               baseline                         
  Cytogenetic abnormalities                                                                                                                                          
  del(13q14.3) only                                                   13                       11.30%                               baseline                         
  del(17p13.1) only                                                   6                        5.22%                                1.65 (0.39--6.97)                0.50
  trisomy 12 only                                                     4                        3.48%                                10.09 (1.60--63.79)              0.014
  del(11q22.3) only                                                   20                       17.39%                               1.60 (0.48--5.38)                0.44
  double del:                                                         16                       13.91%                               1.69 (0.47--6.02)                0.42
  del(13q14.3) and trisomy 12                                         6                        5.22%                                                                 
  del(13q14.3) and del(11q22.3)                                       5                        4.35%                                                                 
  del(17p13.1) and del(11q22.3)                                       2                        1.74%                                                                 
  del(17p13.1) and del(13q14.3)                                       2                        1.74%                                                                 
  del(17p13.1), del(11q22.3) and del(13q14.3)                         1                        0.87%                                                                 
  Negative                                                            56                       48.69%                               0.66 (0.22--1.98)                0.46
  Thrombocytopenia (platelets \< 100 G/L)                                                                                                                            
  Yes                                                                 9                        7.83%                                1.05 (0.47--2.39)                0.90
  No                                                                  106                      92.17%                               baseline                         
  LDH elevated above the reference ranges (81--234 U/L)                                                                                                              
  Yes                                                                 79                       68.7%                                1.45 (0.64--3.26)                0.37
  No                                                                  36                       31.3%                                baseline                         
  B2M elevated above the reference ranges (1.09--2.53 mg/L)                                                                                                          
  Yes                                                                 57                       49.57                                1.58 (0.81--3.09)                0.17
  No                                                                  58                       50.43                                baseline                         
  EBV                                                                                                                                                                
  Positive                                                            62                       53.9%                                7.26 (3.05--17.31)               \< 0.0001
  Negative                                                            53                       46.1%                                baseline                         
  Presence of other cancer                                                                                                                                           
  Yes                                                                 17                       14.8%                                0.84 (0.43--1.67)                0.62
  No                                                                  98                       85.2%                                baseline                         
  Anti-EBV EA IgA                                                                                                                                                    
  Positive                                                            34                       29.6%                                1.29 (1.04--3.62)                0.036
  Negative                                                            81                       70.4%                                baseline                         
  Anti-EBV EA IgG                                                                                                                                                    
  Positive                                                            50                       43.5%                                1.68 (0.92--3.05)                0.091
  Negative                                                            63                       56.5%                                baseline                         
  Anti-EBV EA IgM                                                                                                                                                    
  Positive                                                            18                       15.7%                                1.72 (0.84--3.49)                0.14
  Negative                                                            97                       84.3%                                baseline                         
  Anti-EBV EBNA-1 IgA                                                                                                                                                
  Positive                                                            35                       30.4%                                0.92 (0.52--1.65)                0.79
  Negative                                                            80                       69.6%                                baseline                         
  Anti-EBV EBNA-1 IgG                                                                                                                                                
  Positive                                                            115                      100%                                 \-                               \-
  Negative                                                            0                        0%                                   \-                               \-
  Anti-EBV EBNA-1 IgM                                                                                                                                                
  Positive                                                            25                       21.7%                                1.70 (0.89--3.26)                0.11
  Negative                                                            90                       78.3%                                baseline                         
  Anti-EBV VCA IgA                                                                                                                                                   
  Positive                                                            21                       18.3%                                1.45 (0.72--2.89)                0.29
  Negative                                                            94                       81.7%                                baseline                         
  Anti-EBV VCA IgG                                                                                                                                                   
  Positive                                                            115                      100%                                 \-                               \-
  Negative                                                            0                        0%                                   \-                               \-
  Hypogammaglobulinemia IgA                                                                                                                                          
  Yes                                                                 32                       27.8%                                1.81 (0.91--3.62)                0.091
  No                                                                  83                       72.2%                                baseline                         
  Hypogammaglobulinemia IgG                                                                                                                                          
  Yes                                                                 41                       35.7%                                1.23 (0.65--2.33)                0.52
  No                                                                  74                       64.3%                                baseline                         
  Hypogammaglobulinemia IgM                                                                                                                                          
  Yes                                                                 40                       34.8%                                1.56 (0.79--3.08)                0.20
  No                                                                  75                       65.2%                                baseline                         
  ------------------------------------------------------------------- ------------------------ ------------------------------------ -------------------------------- -------------

\* in the peripheral blood

10.1371/journal.pone.0140178.t002

###### Characteristic of control group.
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  Parameter                                                   Number of controls   Percentages (%)
  ----------------------------------------------------------- -------------------- -----------------
  Age (years)                                                                      
  Median 65.5 (range: 53--79), mean 64.50±7.15                                     
  White blood cell count (G/L)                                                     
  Median 7.02 (range: 4.23--9.63), mean 7.01±1.44                                  
  Lymphocytosis (G/L)                                                              
  Median 2.62 (range: 1.39--4.16), mean 2.65±0.82                                  
  Hemoglobin (g/dL)                                                                
  Median 14.35 (range: 12.5--16.9), mean 14.3±1.19                                 
  Platelets (G/L)                                                                  
  Median 281.5 (range: 186--360), mean 274±49.49                                   
  Lactate dehydrogenase LDH (U/L)                                                  
  Median 155 (range: 111--209), mean 157±27.96                                     
  Beta-2 microglobulin, B2M (mg/L)                                                 
  Median 1.68 (range: 1.06--2.3), mean 1.63±0.39                                   
  IgA (g/L)                                                                        
  Median 2.56 (range: 0.92--3.92), mean 2.39±0.84                                  
  IgG (g/L)                                                                        
  Median 12.79 (range: 10.06--15.47), mean 12.71±1.4                               
  IgM (g/L)                                                                        
  Median 1.61 (range: 1.17--2.19), mean 1.66±0.31                                  
  Splenomegaly                                                                     
  Yes                                                         0                    0%
  No                                                          40                   100%
  Hepatomegaly                                                                     
  Yes                                                         0                    0%
  No                                                          40                   100%
  Thrombocytopenia (platelets\<100 G/L)                                            
  Yes                                                         0                    0%
  No                                                          20                   100%
  LDH elevated above the reference ranges (81--234 U/L)                            
  Yes                                                         0                    0%
  No                                                          20                   100%
  B2M elevated above the reference ranges (1.09--2.53 mg/L)                        
  Yes                                                         0                    0%
  No                                                          20                   100%

This study was approved by the Ethics Committee of the Medical University of Lublin (decision no. KE-0254/227/2010). Written informed consent was obtained from all patients with respect to the use of their blood for scientific purposes.

Examined material {#sec004}
-----------------

Peripheral blood (20 mL) from the basilic vein of CLL patients and healthy controls was collected into EDTA-treated tubes (15 mL) and into tubes containing clot activator (5 mL) (aspiration and vacuum systems Sarstedt, Germany). Immediately after collection, the samples were used for immunophenotyping of lymphocytes, isolation of mononuclear cells for the EBV-DNA copy number determination, serum collection for the determination of specific anti-EBV antibodies concentration, and cytogenetic studies.

Isolation of mononuclear cells and serum {#sec005}
----------------------------------------

Peripheral blood was diluted with 0.9% buffered saline (PBS) without calcium (Ca^2+^) and magnesium (Mg^2+^) (Biochrome AG, Germany) in 1: 1 ratio. The diluted material was built up with 3 mL of Gradisol L (specific gravity 1.077 g/ml; Aqua Medica, Poland), and centrifuged in a density gradient at 700 × g for 20 min. The obtained fraction of peripheral blood mononuclear cells (PBMCs) was collected with Pasteur pipettes and washed twice in PBS without Ca^2+^ and Mg^2+^ for 5 min. Subsequently, the cells were suspended in 1 mL of PBS without Ca^2+^ and Mg^2+^, and either counted in the Neubauer chamber or tested for viability with trypan blue solution (0.4% Trypan Blue Solution, Sigma Aldrich, Germany). Viability below 95% disqualified the cells from further analyses.

Serum was obtained from the samples collected into the tubes containing clot activator, aliquoted, and stored at --80°C for enzyme-linked immunosorbent assay (ELISA) test.

Isolation of DNA and determination of the EBV copy number {#sec006}
---------------------------------------------------------

DNA from 5 × 10^6^ PBMCs was isolated manually with the QIAamp DNA Blood Mini Kit (QIAGEN, Germany). The procedure for isolation followed the manufacturer's protocol, with a modified volume of DNA elution. Concentration and purity of the isolated DNA were verified with the BioSpec-nano spectrophotometer (Shimadzu, Japan). The EBV-DNA copy number in PBMCs was determined with the ISEX variant of the EBV PCR kit (GeneProof, Czech Republic). Qualitative and quantitative diagnostics of EBV was performed using the Real Time Polymerase Chain Reaction (RT-PCR). Specific conservative DNA sequence of a single-copy gene for the EBV nuclear antigen 1 (EBNA-1) was amplified in the course of the PCR process. The number of viral DNA copies/*μ*L of the eluent was adjusted for the efficiency of the DNA isolation process, and then it was expressed as the viral DNA copy number/*μ*g DNA. All the samples were examined in duplicates. A negative control, i.e. the pure buffer used for DNA elution, was amplified in every case. As the sensitivity of the system amounts to 10 copies/μL, all the samples with the EBV-DNA copy number below this detection threshold were considered EBV-negative \[EBV(--)\]. The PCR was performed with the 7300 Real Time PCR System (Applied Biosystems). The reaction was conducted on MicroAmp® Optical 96-Well Reaction Plates (Life Technologies) with MicroAmp® Optical Adhesive Film (Life Technologies).

Assessment of activated T and B cells {#sec007}
-------------------------------------

A standard, whole-blood assay with erythrocyte cell lysis was used for preparing the peripheral blood specimens. The cells were phenotypically characterized by incubation (20 min in the dark at room temperature) with a combination of relevant fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, and CyChrome-labelled monoclonal antibodies (MoAbs). Immunofluorescence studies were performed using a combination of the following MoAbs: CD3 PE, CD19 PE, CD5 FITC/CD19 PE, CD4 PE, CD8 PE, CD8 FITC/CD4 PE, CD25 CyChrome, and CD69 CyChrome, purchased from BD Biosciences (USA). Finally, cells were washed and analyzed by flow cytometry, performed on a BD FACSCalibur System. Five data parameters were acquired and stored: linear forward and side scatter (FSC, SSC), log FL-1 (FITC), log FL-2 (PE), and log FL-3 (PE-Cy5). For each analysis, 20,000 events were acquired and analyzed using CellQuest Pro software. Isotype-matched antibodies were used to verify the staining specificity and as a guide for setting the markers to delineate positive and negative populations. Mean fluorescence intensity (MFI) and the percentage of cells expressing surface markers were analyzed.

Analysis of CD38 and ZAP-70 expression in CLL cells {#sec008}
---------------------------------------------------

CLL cells were stained for CD38 antigen and ZAP-70 protein expression (as described previously by Hus et al. \[[@pone.0140178.ref011]\]) and analyzed using flow cytometry. The cut-off point for CD38 and ZAP-70 positivity in leukemic cells was ≥30% and ≥20%, respectively.

I-FISH analysis {#sec009}
---------------

PBMCs were cultivated for 24 hours in RPMI 1640 medium without mitogen stimulation. After hypotonic treatment and methanol---acetic acid 3: 1 fixation, cell suspensions were dropped onto microscopic slides and used directly for I-FISH. The commercially available Vysis probes (Abbott Molecular Europe, Wiesbaden, Germany) LSI ATM SpectrumOrange/CEP 11 SpectrumGreen Probe, and LSI TP53 SpectrumOrange/CEP 17 SpectrumGreen Probe were used. At least 200 nuclei were analyzed for each probe. The cut-off levels for positive values for normal controls were 2.5% (mean ± SD).

Anti-EBV immunoassay {#sec010}
--------------------

Commercial enzyme-linked immunosorbent assay (ELISA) kits, purchased from IBL International (Germany) for a quantitative determination of specific anti-EBV antibodies in human serum were used. Protocols followed were in accordance with the manufacturer's recommendations. The ELISA Reader Victor TM3 (PerkinElmer, USA) was used.

Statistical analysis {#sec011}
--------------------

Normal distribution of continuous variables was tested using the Shapiro-Wilk test. Statistical characteristics of the continuous variables were presented as medians, minimum and maximum values, as well as arithmetic means and their standard deviations (SD). The Student *t*-test was used for independent variables, and the Mann-Whitney *U*-test was used for intergroup comparisons. The power and direction of relationships between pairs of continuous variables were determined on the basis of the values of Spearman's coefficient of rank correlation (*R*). The distributions of discrete variables in the studied groups were compared with the Pearson's Chi-square test or the Fisher's exact test. The survival curves were constructed with the Kaplan-Meier method, and the proportions of survivors within the studied groups were compared with the log-rank test. Univariable and multivariable Cox proportional hazard regression models were used to determined association between patients characteristics and time to first treatment. For the multivariable model, stepwise variable selection was used. Significant variables (p\<0.1) were tested for inclusion in the regression models, and nonsignificant variables were removed sequentially until only those significant at p\<0.05 remained.

Receiver operating characteristic (ROC) curves were generated for significant predictor variables of EBV(+) CLL patients. Areas under the ROC curves (AUCs) were calculated for each parameter and compared. All the calculations were carried out with Statistica 10 (StatSoft®, USA) package, with the level of significance set at *P* \< 0.05.

Results {#sec012}
=======

The PBMCs of 115 CLL patients and 40 controls were tested for the presence of EBV-DNA with an aid of real-time PCR. A total of 62 (53.91%) CLL patients presented with a large number of EBV-DNA copies (more than 10 copies/*μ*L). The following three groups were identified on the basis of this criterion: (a) CLL patients whose PBMCs showed the presence of the EBV-DNA, i.e. the EBV(+) group, (b) CLL patients whose PBMCs lacked the EBV-DNA, i.e. the EBV(--) group and (c) healthy controls.

In univariable analysis, among clinical and biochemical parameters of CLL patients both traditional and new prognostic factors associated with shorter time to first treatment turn out to be statistically significant ([Table 1](#pone.0140178.t001){ref-type="table"}). We found that categorical variables such as the splenomegaly, trisomy 12, CD38, and positive anti-EBV EA IgA were associated with time to first treatment ([Table 1](#pone.0140178.t001){ref-type="table"}). Among continuous variables lower hemoglobin, higher beta-2 microglobulin and LDH, higher CD19+CD25+ cells, CD19+CD69+ cells, CD3+CD69+ cells, CD19+CD5+CD38+ cells and CD19+CD5+CD23+ cells had significant association with time to treatment. Higher level of anti-EBV: EA IgG, EBNA IgG and VCA IgG were associated with shorter time to first treatment. Interestingly, EBV(+) patients had more than 7 times shorter time to first treatment comparing to EBV(-) patients. This phenomenon was confirmed during multivariable analysis. The multivariable Cox analysis identified the higher beta-2-microglobulin (HR = 1.43; p = 0.0033), enlarged spleen (HR = 4.70; p\<0.0001), EBV presence (HR = 23.39; p\<0.0001) and lower anti-EBV EBNA-1 IgM level (HR = 0.98; p = 0.0089) as independent predictors for shorter time to first treatment ([Table 3a](#pone.0140178.t003){ref-type="table"}). Since the Cox proportional hazard regression model showed highly statistically significant association of EBV(+) with progression of illness, a ROC curve was drawn to test the variables predictive validity in EBV(+) CLL patients ([Table 3b](#pone.0140178.t003){ref-type="table"}). As the area under the curve shows ([Fig 1](#pone.0140178.g001){ref-type="fig"}), CD19+CD25+ cells \[%\] in the peripheral blood parameter was the most sensitive and specific to determine EBV(+) (AUC = 0.854). [Fig 2](#pone.0140178.g002){ref-type="fig"} presents a Kaplan-Meier curve illustrating the time to first treatment depending on the EBV-DNA copy number/*μ*g DNA isolated from PBMCs ([Fig 2a](#pone.0140178.g002){ref-type="fig"}) and a Kaplan-Meier curve illustrating the probability of lymphocyte doubling-free survival depending on the EBV-DNA copy number/*μ*g DNA isolated from PBMCs ([Fig 2b](#pone.0140178.g002){ref-type="fig"}). [Table 4](#pone.0140178.t004){ref-type="table"} presents the comparison between clinical and laboratory parameters in CLL EBV(+) patients, CLL EBV(--) patients and the study group. [Table 5](#pone.0140178.t005){ref-type="table"} presents an assessment of anti-EBV antibody concentrations in relation to the presence or absence of EBV-DNA copies in PBMCs of CLL patients and control group. [Fig 3](#pone.0140178.g003){ref-type="fig"} presents statistically significant correlations between activated T CD3+ and B CD19+ cells in CLL patients.

10.1371/journal.pone.0140178.t003

###### 

**(a).** Multivariable Cox Proportional Hazards Model for time to first treatment. **(b).** Receiver operating characteristic analysis to determine diagnostic accuracy in differentiation of patients with EBV(+) and EBV(-).
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  ------------------------------------------------------------------- ---------------------- ------------------------------------ ------------- ----------
  **(a)**                                                                                                                                       
  **Parameter**                                                       **Hazard Ratio**       **95% CI for hazard ratio**          **P value**   
                                                                                             **Lower**                            **Upper**     
  Beta-2-microglobulin \[mg/dL\]                                      1.43                   1.12                                 1.83          0.0033
  Anti-EBV EBNA-1 IgM \[U/mL\]                                        0.91                   0.84                                 0.98          0.0089
  EBV positive                                                        23.29                  7.7                                  70.39         \<0.0001
  Splenomegaly positive                                               4.70                   2.20                                 10.01         \<0.0001
  **Parameter**                                                       **Hazard Ratio**       **95% CI for hazard ratio**          **P value**   
                                                                                             **Lower**                            **Upper**     
  Beta-2-microglobulin \[mg/dL\]                                      1.45                   1.15                                 1.82          0.0017
  EBV positive                                                        32.93                  9.67                                 112.18        \<0.0001
  Splenomegaly positive                                               3.33                   1.64                                 6.79          0.0009
  Anti-EBV EA IgG positive                                            0.33                   0.15                                 0.72          0.0055
  **(b)**                                                                                                                                       
  **Parameter**                                                       **Prognostic value**   **Area under the ROC curve (AUC)**   **95%CI**     
  Beta-2-microglobulin (mg/dL)                                        2.63                   0.742                                0.65--0.83    
  Lactate dehydrogenase (U/L)                                         261                    0.739                                0.65--0.83    
  CD19+CD25+ cells \[%\] [\*](#t003fn001){ref-type="table-fn"}        54.75                  0.854                                0.79--0.92    
  CD19+CD69+ cells \[%\] [\*](#t003fn001){ref-type="table-fn"}        29.81                  0.74                                 0.65--0.83    
  CD19+CD5+ZAP-70+ cells \[%\][\*](#t003fn001){ref-type="table-fn"}   6.31                   0.726                                0.63--0.82    
  CD19+CD5+CD38+ cells \[%\][\*](#t003fn001){ref-type="table-fn"}     10.74                  0.838                                0.76--0.91    
  CD19+CD5+CD23+ cells \[%\] [\*](#t003fn001){ref-type="table-fn"}    75.59                  0.707                                0.61--0.80    
  ------------------------------------------------------------------- ---------------------- ------------------------------------ ------------- ----------

\* in the peripheral blood

10.1371/journal.pone.0140178.t004

###### Comparison between clinical and laboratory parameters in CLL EBV(+) patients, CLL EBV(-) patients and the control group.
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  Parameter                                                               Patients EBV(+)   Patients EBV(-)        Control group   Patients EBV(+) vs. EBV(-)   Patients EBV(+) vs. Control group   Patients EBV(-) vs. Control group                                              
  ----------------------------------------------------------------------- ----------------- ---------------------- --------------- ---------------------------- ----------------------------------- ----------------------------------- ------ ---------- ------ ---------- ------ ----------
  Age \[years\]                                                           64.7±9.7          64.0 (39--89)          62.8±10.1       65.0 (38--79)                64.5±7.1                            64.0 (53--79)                       0.98   0.33       0.08   0.94       0.66   0.51
  Elapsed time from CLL diagnosis to the treatment admission \[months\]   5.9±9.0           0.5 (0--38)            9.0±17.1        0 (0--72)                    N/A                                 N/A                                 1.86   0.062      N/A    N/A        N/A    N/A
  Observation period \[months\]                                           33.4±11.8         32.5 (10.5--72.0)      34.8±15.1       33.0 (14--80)                N/A                                 N/A                                 0.04   0.97       N/A    N/A        N/A    N/A
  Lymphocytosis doubling time \[months\]                                  6.8±6.2           6.0 (0--28)            10.9±20.8       10 (0--94)                   N/A                                 N/A                                 3.50   0.0005     N/A    N/A        N/A    N/A
  Leukocytosis \[x10\^3 cells/μL\]                                        37.4±21.3         29.1 (11.2--93.7)      36.8±25.0       30.5 (9.7--128.0)            7.0±1.4                             7.0 (4.2--9.6)                      0.64   0.52       6.69   \<0.0001   6.55   \<0.0001
  Lymphocytosis \[x10\^3 cells/μL\]                                       31.4±20.3         24.1 (8.9--87.5)       30.7±24.4       24.6 (6.2--124.0)            2.7±0.9                             2.6 (1.4--5.2)                      0.72   0.47       6.69   \<0.0001   6.55   \<0.0001
  Hemoglobin \[g/dL\]                                                     12.1±1.4          12.1 (9.0--15.7)       14.2±1.3        14.2 (9.9--16.8)             14.3±1.2                            14.4 (12.5--16.9)                   8.35   \<0.0001   6.41   \<0.0001   0.36   0.72
  Platelets \[x10\^3 cells/μL\]                                           155.8±54.6        146.0 (57.0--295.0)    196.9±55.2      194.0 (80.0--309.0)          279.0±57.0                          281.5 (186.0--403.0)                4.0    0.0001     8.68   \<0.0001   5.61   \<0.0001
  Beta-2-microglobulin \[mg/L\]                                           3.3±1.4           3.0 (1.3--8.1)         2.3±0.8         2.3 (1.1--5.9)               1.6±0.4                             1.7 (1.1--2.3)                      4.47   \<0.0001   5.74   \<0.0001   4.09   \<0.0001
  Lactate dehydrogenase \[U/L\]                                           354.3±143.0       323.5 (114.0--955.0)   250.8±94.5      229.0 (96.0--466.0)          157.0±28.0                          155.5 (111.0--209.0)                4.41   \<0.0001   6.33   \<0.0001   4.33   \<0.0001
  CD19+CD25+ cells \[%\][\*](#t004fn003){ref-type="table-fn"}             66.4±15.6         66.4 (34.1--93.9)      41.5±17.2       44.1 (6.7--72.3)             2.8±1.5                             2.8 (0.2--5.2)                      6.52   \<0.0001   6.69   \<0.0001   6.55   \<0.0001
  MFI value of CD25 on CD19+ cells[\*](#t004fn003){ref-type="table-fn"}   82.3±48.6         73.6 (13.9--213.9)     51.9±22.8       49.8 (12.8--105.9)           34.3±18.0                           29.8 (6.4--70.1)                    3.36   0.0008     4.42   \<0.0001   2.99   0.003
  CD19+CD69+ cells \[%\][\*](#t004fn003){ref-type="table-fn"}             38.4±19.3         39.6 (2.7--78.8)       22.5±16.1       20.9 (0.6--70.1)             1.0±0.8                             0.8 (0.1--3.6)                      4.45   \<0.0001   6.66   \<0.0001   6.38   \<0.0001
  MFI value of CD69 on CD19+ cells[\*](#t004fn003){ref-type="table-fn"}   87.9±42.0         77.9 (24.6--209.9)     51.5±31.2       40.9 (21.6--177.9)           22.8±13.1                           18.6 (7.3--59.9)                    5.37   \<0.0001   6.27   \<0.0001   4.81   \<0.0001
  CD3+CD25+ cells \[%\][\*](#t004fn003){ref-type="table-fn"}              23.7±15.7         21.5 (1.2--59.4)       15.5±11.3       13.0 (0.6--45.1)             7.8±2.7                             8.0 (1.1--11.5)                     2.77   0.006      4.04   \<0.0001   2.65   0.008
  MFI value of CD25 on CD3+ cells [\*](#t004fn003){ref-type="table-fn"}   71.4±37.2         68.5 (19.4--170.0)     50.6±32.6       41.2 (9.2--129.0)            41.6±17.1                           41.5 (16.7--73.7)                   3.12   0.002      3.15   0.002      0.44   0.66
  CD3+CD69+ cells \[%\] [\*](#t004fn003){ref-type="table-fn"}             5.9±5.6           4.1 (0.1--29.3)        3.2±2.8         2.4 (0.1--16.0)              1.7±0.8                             1.8 (0.4--3.0)                      3.20   0.001      4.29   \<0.0001   1.94   0.053
  MFI value of CD69 on CD3+ cells[\*](#t004fn003){ref-type="table-fn"}    71.1±48.0         57.5 (10.6--192.2)     47.0±27.8       40.9 (10.2--120.9)           41.6±28.3                           29.9 (10.4--113.9)                  2.78   0.005      2.85   0.004      0.80   0.43
  CD19+ZAP-70+ cells \[%\] [\*](#t004fn003){ref-type="table-fn"}          20.9±13.5         18.1 (0.9--61.3)       10.9±9.5        5.9 (0.5--33.8)              N/A                                 N/A                                 4.17   \<0.0001   N/A    N/A        N/A    N/A
  CD19+CD38+ cells \[%\] [\*](#t004fn003){ref-type="table-fn"}            35.7±26.4         33.8 (0.4--91.4)       8.0±14.9        1.6 (0.2--65.0)              N/A                                 N/A                                 6.23   \<0.0001   N/A    N/A        N/A    N/A
  CD19+CD5+CD23+ cells \[%\][\*](#t004fn003){ref-type="table-fn"}         82.9±10.6         86.5 (50.7--95.9)      73.8±13.0       74.8 (46.1--92.4)            N/A                                 N/A                                 3.82   0.0001     N/A    N/A        N/A    N/A
  CD3+ cells \[%\][\*](#t004fn003){ref-type="table-fn"}                   10.5±7.9          8.7 (1.2--33.4)        10.1±6.6        8.3 (1.0--28.6)              68.2±5.0                            67.8 (61.5--78.6)                   0.13   0.90       6.69   \<0.0001   6.55   \<0.0001
  CD19+ cells \[%\][\*](#t004fn003){ref-type="table-fn"}                  85.2±10.3         86.4 (51.5--97.8)      85.7±8.2        86.7 (67.0--98.3)            12.2±2.9                            11.8 (7.8--16.6)                    0.20   0.84       6.69   \<0.0001   6.55   \<0.0001
  CD5+CD19+ cells \[%\][\*](#t004fn003){ref-type="table-fn"}              84.2±11.5         86.8 (54.9--99.6)      87.0±8.7        86.5 (70.0--99.7)            13.2±3.6                            13.1 (5.7--19.6)                    0.94   0.35       6.69   \<0.0001   6.55   \<0.0001
  Serum IgA concentration \[g/L\]                                         1.7±1.2           1.4 (0.1--5.4)         1.2±0.7         1.1 (0.2--2.9)               2.4±0.8                             2.6 (0.9--3.9)                      2.05   0.041      2.96   0.003      4.82   \<0.0001
  Serum IgG concentration \[g/L\]                                         9.8±4.1           9.6 (3.5--19.4)        8.3±2.8         8.3 (3.2--14.7)              12.7±1.4                            12.8 (10.1--15.5)                   1.81   0.07       3.43   0.0006     5.31   \<0.0001
  Serum IgM concentration \[g/L\]                                         0.7±0.5           0.6 (0.04--3.1)        0.6±0.5         0.5 (0.05--2.2)              1.7±0.3                             1.6 (1.2--2.2)                      1.36   0.17       5.77   \<0.0001   5.81   \<0.0001

MFI, Mean Fluorescent Intensity;

N/A., not applicable;

\* in the peripheral blood

10.1371/journal.pone.0140178.t005

###### Serum anti-EBV antibody concentrations (i.e. IgG, IgM, IgA) in EBV(+) CLL patients, EBV(-) CLL patients, and the control group.
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  Antibody serum concentration \[U/mL\]   Patients EBV(+)   Patients EBV(-)       Control group   PatientsEBV(+) vs. EBV(-)   Patients EBV(+) vs. Control group   Patients EBV(-) vs. Control group                                              
  --------------------------------------- ----------------- --------------------- --------------- --------------------------- ----------------------------------- ----------------------------------- ------ ---------- ------ ---------- ------ -------
  Anti-EBV EA IgA                         51.5±113.5        6.7 (2.4--580.4)      5.9±5.2         4.8 (1.0--33.3)             3.7±1.7                             3.7 (1.6--7.5)                      2.91   0.004      3.83   0.0001     2.43   0.015
  Anti-EBV EA IgG                         87.1±105.6        38.1 (3.2--381.1)     16.0±20.3       8.2 (1.9--94.8)             8.5±4.5                             8.2 (1.7--15.9)                     5.60   \<0.0001   4.78   \<0.0001   0.60   0.55
  Anti-EBV EA IgM                         7.4±10.2          4.1 (1.4--62.7)       4.3±2.9         3.6 (0.8--14.2)             3.6±2.0                             3.0 (1.0--7.3)                      1.83   0.067      1.81   0.071      0.40   0.69
  Anti-EBV EBNA-1 IgA                     11.1±13.9         5.3 (1.2--78.5)       6.3±4.8         5.4 (1.5--30.4)             4.0±1.9                             3.6 (1.2--7.0)                      0.34   0.73       1.55   0.12       2.20   0.028
  Anti-EBV EBNA-1 IgG                     219.9±328.3       87.8 (22.5--1701.8)   60.7±32.5       55.7 (22.4--181.7)          63.0±26.5                           55.8 (34.0--139.8)                  3.18   0.001      1.65   0.10       0.62   0.53
  Anti-EBV EBNA-1 IgM                     7.6±5.0           6.0 (1.8--20.7)       4.9±2.3         4.8 (0.9--10.8)             4.9±1.7                             4.7(2.2--7.8)                       2.53   0.011      1.67   0.095      0.30   0.76
  Anti-EBV VCA IgA                        12.7±10.7         9.3 (1.9--50.9)       8.1±4.8         5.8 (2.0--19.8)             6.4±3.7                             5.7 (1.4--13.7)                     1.57   0.12       2.24   0.025      1.30   0.19
  Anti-EBV VCA IgG                        207.0±83.7        222.8 (30.3--352.8)   150.3±90.9      134.6 (23.8--358.1)         148.0±71.2                          139.3 (33.4--274.9)                 3.52   0.0004     2.97   0.003      0.15   0.88

![Comparison of the different immunological parameters found in peripheral blood for their ability to predict the presence of EBV.\
ROC curves were used to compare the sensitivity and specificity of immunological parameters (e.g. CD19+CD25+) in EBV(+) and EBV(--) CLL patients. The percentage of CD19+CD25+ cells in the peripheral blood was the most sensitive and specific parameter for determining a positive EBV reading (AUC = 0.854).](pone.0140178.g001){#pone.0140178.g001}

![The time to first treatment and the probability of lymphocyte doubling-free survival depends on the EBV-DNA copy number in peripheral blood mononuclear cells (PBMCs) from chronic lymphocytic leukemia patients.\
(a) Kaplan-Meier curve illustrating the time to first treatment depending on the EBV-DNA copy number/μg DNA isolated from PBMCs; (b) Kaplan-Meier curve illustrating the probability of lymphocyte doubling-free survival depending on the EBV-DNA copy number/*μ*g DNA isolated from PBMCs.](pone.0140178.g002){#pone.0140178.g002}

![Statistically significant correlations between activated CD3+ T cells and CD19+ B cells in CLL patients and EBV-DNA viral load.\
(a) Positive correlation between the frequencies of CD19+CD25+ cells (%) and EBV-DNA copies/*μ*g DNA; (b) positive correlation between the mean fluorescent intensity (MFI) of CD25 on CD19+ cells (%) and EBV-DNA copies/*μ*g DNA; (c) positive correlation between the frequencies of CD19+CD69+ cells (%) and EBV-DNA copies/*μ*g DNA; (d) positive correlation between the MFI of CD69 on CD19+ cells (%) and EBV-DNA copies/*μ*g DNA; (f) positive correlation between the frequencies of CD3+CD25+ cells (%) and EBV-DNA copies/*μ*g DNA; (g) positive correlation between the MFI of CD25 on CD3+ cells (%) and EBV-DNA copies/*μ*g DNA; (h) positive correlation between the frequencies of CD3+CD69+ cells (%) and EBV-DNA copies/*μ*g DNA; (i) positive correlation between the MFI of CD69 on CD3+ cells (%) and EBV-DNA copies/*μ*g DNA.](pone.0140178.g003){#pone.0140178.g003}

Discussion {#sec013}
==========

A total of 20 CLL patients had more than 1000 EBV-DNA copies/*μ*g of PBMC DNA; the EBV-DNA copy number of the remaining patients ranged between 100 and 1000 (*N* = 22) or between 10 and 100 (*N* = 20). These results are similar to the data reported by Kimura et al. \[[@pone.0140178.ref012]\], according to whom the EBV-DNA copy number per *μ*g DNA extracted from PBMCs of patients with EBV-related lymphoproliferative disorders and infectious mononucleosis ranges between 10 and 10000. In contrast, the EBV-DNA copy number in most healthy controls and immunocompromised patients after organ transplantation did not exceed 10 copies/*μ*g DNA. Both Kimura et al. \[[@pone.0140178.ref012]\] and Stevens et al. \[[@pone.0140178.ref013]\] postulated that more than 100--1000 EBV-DNA copies/*μ*g DNA isolated from examined material are associated with clinical signs of EBV infection, manifesting as the chronic active EBV disease (CAEBV) or post-transplant lymphoproliferative disease. These findings and the results of our study point to a potential presence of a CLL subtype being associated with EBV infection. Moreover, an increase in the EBV-DNA copy number was documented in most of our patients during approximately 2-year follow-up.

We revealed the presence of EBV-DNA in PBMCs and isolated B lymphocytes in more than a half of our CLL patients. To the best of our knowledge, no previous studies distinguished between the CLL forms being associated with EBV infection or unrelated to this virus. The EBV-associated form of CLL seems to be characterized by more aggressive phenotype. We showed that the EBV-DNA copy number in PBMCs of patients with hepatomegaly or thrombocytopenia and individuals who required earlier implementation of treatment was significantly higher than that in the remaining individuals. A number of previous studies documented the role of EBV in induction of thrombocytopenia. While the presence of EBV in patients with infectious mononucleosis is usually associated with a slight decrease in platelet count, in the case of CAEBV, it can be associated with severe thrombocytopenia, anemia (usually of autoimmune origin), and splenomegaly (resulting from lymphocyte infiltration) or even liver failure \[[@pone.0140178.ref014], [@pone.0140178.ref015]--[@pone.0140178.ref016]\].

Moreover, we showed that the EBV-DNA copy number correlated significantly with serum concentrations of beta-2-microglobulin and LDH. As early as 1981, Ibsen et al. \[[@pone.0140178.ref017]\] revealed that the level of beta-2-microglobulin is at its highest during initial stages of infectious mononucleosis, and subsequently, within 3 weeks to 3 months after recovery, it normalizes to its baseline level. The fact that concentration of beta-2-microglobulin constitutes an established predictive factor in CLL patients may suggest that the elevated level of this protein is associated with EBV infection in at least some of the cases \[[@pone.0140178.ref018]\]. Furthermore, we revealed significant associations between other negative prognostic factors such as high cytoplasmic expression of ZAP-70 \[[@pone.0140178.ref019]\], surface expression of CD38 in leukemic cells \[[@pone.0140178.ref020]\], surface expression of CD23, CD25, and CD69 \[[@pone.0140178.ref021], [@pone.0140178.ref022]\], as well as unfavorable genetic mutations \[[@pone.0140178.ref023]\], and EBV-DNA copy number.

Tsimberidou et al. reported that 38% of CLL patients had evidence of EBV infection by in situ hybridization for EBV EBER1, a small noncoding RNA species \[[@pone.0140178.ref024]\]. Tarrand et al. \[[@pone.0140178.ref025]\] reported that LMP1 mRNA levels were higher in CLL patients than in healthy subjects (14% vs. 1% of healthy controls), suggesting that EBV late gene expression occurs at least in a subset of CLL cells. We demonstrate significant associations between viral load of EBV-DNA and various clinical and pathologic variables among CLL patients, including associations with progression and time to treatment. These findings are in line with conclusions made by Visco et al. \[[@pone.0140178.ref026]\] who postulated that EBV-DNA load at presentation is an independent predictor of overall survival in patients with CLL.

Conclusions {#sec014}
===========

In conclusion, more than a half of CLL patients presented with CLL EBV-DNA in their PBMCs, whereas no detectable amounts of genetic material for this pathogen were found in healthy controls. Greater EBV-DNA copy number was associated with shorter overall survival and time to progression in CLL patients. Positive correlation between EBV-DNA copy number and established unfavorable prognostic factors of CLL implies that increased EBV load in peripheral blood may predict poor clinical outcomes of CLL.
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